Max Healthcare Institute Intrinsic Value
Max Healthcare Institute intrinsic value. Max Healthcare Institute (MAXHEALTH) median intrinsic value is ₹245.10 from 10 valuation models (range ₹163–₹409), vs current price ₹817.00 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Max Healthcare Institute share price chart.
MAXHEALTH Valuation Methods Summary — DCF, Graham Number & P/E
Max Healthcare Institute intrinsic value across 10 models vs current price ₹817.00 — upside/downside and value range per method. Read MAXHEALTH dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹245.10 | ₹196.08 - ₹294.12 | -70.0% | EPS: ₹14.08, Sector P/E: 12x |
| Book Value Method | asset | ₹163.40 | ₹147.06 - ₹179.74 | -80.0% | Book Value/Share: ₹110.45, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹245.10 | ₹220.59 - ₹269.61 | -70.0% | Revenue/Share: ₹90.07, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹326.80 | ₹294.12 - ₹359.48 | -60.0% | EBITDA: ₹2616.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹326.80 | ₹261.44 - ₹392.16 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹245.10 | ₹220.59 - ₹269.61 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹245.10 | ₹220.59 - ₹269.61 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹408.50 | ₹367.65 - ₹449.35 | -50.0% | ROE: 12.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹245.10 | ₹220.59 - ₹269.61 | -70.0% | EPS: ₹14.08, BVPS: ₹110.45 |
| Dividend Yield Method | dividend | ₹245.10 | ₹220.59 - ₹269.61 | -70.0% | DPS: ₹2.00, Target Yield: 3.5% |
MAXHEALTH Intrinsic Value vs Market Price — All Valuation Models
Max Healthcare Institute fair value range ₹163–₹409 vs current market price ₹817.00 across 10 valuation models. Compare with Max Healthcare Institute value estimation to assess whether the stock is under or overvalued.
MAXHEALTH Intrinsic Value Analysis — Undervalued or Overvalued?
Max Healthcare Institute median intrinsic value ₹245.10, current price ₹817.00 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of MAXHEALTH?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Max Healthcare Institute (MAXHEALTH) is ₹245.10 (median value). With the current market price of ₹817.00, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹163.40 to ₹408.50, indicating ₹163.40 - ₹408.50.
Is MAXHEALTH undervalued or overvalued?
Based on our multi-method analysis, Max Healthcare Institute (MAXHEALTH) appears to be trading above calculated value by approximately 70.0%.
MAXHEALTH Financial Health — Key Ratios vs Industry Benchmarks
Max Healthcare Institute financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 12.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MAXHEALTH Cash Flow Quality — Operating & Free Cash Flow
Max Healthcare Institute operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,633 Cr | ₹789 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹1,438 Cr | ₹642 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹1,122 Cr | ₹496 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹1,209 Cr | ₹616 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹741 Cr | ₹359 Cr | Positive Free Cash Flow | 7/10 |